CAR-T Cell Therapy for Resistant B-Cell Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests CY-219, a type of cell therapy that trains your immune cells to fight B-cell lymphoma that has come back or stopped responding to standard treatments. The study evaluates whether this approach is safe and effective for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell lymphoma (confirmed by biopsy) that has relapsed or stopped responding to treatment
- You've already received anti-CD20 antibody therapy and anthracycline-based chemotherapy
- Your heart, lungs, liver, and kidneys are working well enough to handle the treatment
- You're at least 18 years old and able to attend all study visits and tests
- You're expected to live at least 3 months from enrollment
- You agree to use contraception if you could become pregnant, for one year after the cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.